A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs)

被引：0
作者：
Reidy-Lagunes, Diane [1 ,2 ]
Pietanza, M. Catherine [1 ,2 ]
Sega, Michal [1 ,2 ]
Capanu, Marinela [1 ,2 ]
Saltz, Leonard [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
PANCREAS | 2014年 / 43卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：503 / 503
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors
    Tolcher, A. W.
    Baird, R. D.
    Patnaik, A.
    Garcia, V. Moreno
    Papadopoulos, K. P.
    Garrett, C. R.
    Olmos, D.
    Shannon, K. A.
    Zazulina, V.
    Rubin, E. H.
    Smith, I. C.
    Ryan, J.
    Smith, P. D.
    Taylor, A.
    Learoyd, M.
    Lupinacci, L.
    Yan, L.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    L Rhoda Molife
    Li Yan
    Joanna Vitfell-Rasmussen
    Adriane M Zernhelt
    Daniel M Sullivan
    Philippe A Cassier
    Eric Chen
    Andrea Biondo
    Ernestina Tetteh
    Lillian L Siu
    Amita Patnaik
    Kyriakos P Papadopoulos
    Johann S de Bono
    Anthony W Tolcher
    Susan Minton
    Journal of Hematology & Oncology, 7
  • [33] Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
    Biondo, A.
    Yap, T. A.
    Yan, L.
    Patnaik, A.
    Fearen, I.
    Baird, R. D.
    Papadopoulos, K. P.
    Delgado, L. M.
    Taylor, A.
    Lupinacci, L.
    Blackman, S. C.
    Decordova, S.
    Tall, M.
    Heaton, S.
    Garrett, M. D.
    Sullivan, D.
    De Bono, J. S.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    Molife, L. Rhoda
    Yan, Li
    Vitfell-Rasmussen, Joanna
    Zernhelt, Adriane M.
    Sullivan, Daniel M.
    Cassier, Philippe A.
    Chen, Eric
    Biondo, Andrea
    Tetteh, Ernestina
    Siu, Lillian L.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    de Bono, Johann S.
    Tolcher, Anthony W.
    Minton, Susan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [35] A Phase I Trial of MK-2206 in Children with Refractory Malignancies: A Children's Oncology Group Study
    Fouladi, Maryam
    Perentesis, John P.
    Phillips, Christine L.
    Leary, Sarah
    Reid, Joel M.
    McGovern, Renee M.
    Ingle, Ashish M.
    Ahern, Charlotte H.
    Ames, Matthew M.
    Houghton, Peter
    Doyle, L. Austin
    Weigel, Brenda
    Blaney, Susan M.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (07) : 1246 - 1251
  • [36] A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors
    Matthew H. Kulke
    Bingyan Wu
    David P. Ryan
    Peter C. Enzinger
    Andrew X. Zhu
    Jeffrey W. Clark
    Craig C. Earle
    Ann Michelini
    Charles S. Fuchs
    Digestive Diseases and Sciences, 2006, 51 : 1033 - 1038
  • [37] A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Kulke, Matthew H.
    Wu, Bingyan
    Ryan, David P.
    Enzinger, Peter C.
    Zhu, Andrew X.
    Clark, Jeffrey W.
    Earle, Craig C.
    Michelini, Ann
    Fuchs, Charles S.
    DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (06) : 1033 - 1038
  • [38] Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Strosberg, Jonathan
    Campos, Tiffany
    Kvols, Larry
    PANCREAS, 2010, 39 (02) : 280 - 281
  • [39] A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma, Cynthia X.
    Sanchez, Cesar
    Gao, Feng
    Crowder, Robert
    Naughton, Michael
    Pluard, Timothy
    Creekmore, Allison
    Guo, Zhanfang
    Hoog, Jeremy
    Lockhart, A. Craig
    Doyle, Austin
    Erlichman, Charles
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2650 - 2658
  • [40] A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+breast cancer
    Nazeef, Moniba
    Tevaarwerk, Amye J.
    Eickhoff, Jens
    Burkard, Mark E.
    Heideman, Jennifer
    Liu, Glenn
    Flynn, Chris
    Kolesar, Jill M.
    Wisinski, Kari B.
    CANCER RESEARCH, 2015, 75
12345